Welcome to our dedicated page for Nevro news (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on Nevro stock.
Nevro Corp. (NYSE: NVRO) is a global medical device company headquartered in Redwood City, California and focused on technologies for chronic pain treatment. This news page aggregates company announcements, financial updates and clinical evidence related to Nevro’s proprietary 10 kHz spinal cord stimulation (SCS) therapy and sacroiliac (SI) joint fusion offerings.
Investors and observers can follow Nevro’s regular disclosures on quarterly and full-year financial results, including worldwide and U.S. revenue, international revenue, operating performance and cash position. The company also issues updates on strategic matters, such as its announced definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction, which remains subject to shareholder and regulatory approvals and other customary conditions.
Because Nevro operates in chronic pain management, a significant portion of its news flow highlights clinical and product developments. These include publications of data on 10 kHz SCS in painful diabetic neuropathy and Type 2 diabetes, showing durable pain relief and reported improvements in measures such as HbA1c, weight and sleep, as well as biomechanical studies of the Nevro1 SI Joint Fusion System. Product and regulatory updates, such as CE Mark Certification in Europe for the HFX iQ SCS system and launches of HFX iQ with HFX AdaptivAI, also feature prominently.
In addition, Nevro regularly announces employee inducement equity awards under NYSE Rule 303A.08, reflecting hiring activity, and provides commentary on commercial execution, restructuring efforts and marketing initiatives. For anyone tracking NVRO, this news feed offers a centralized view of Nevro’s financial performance, clinical evidence, product expansion and corporate transactions over time.
Nevro Corp. (NYSE: NVRO) will participate in the BofA Securities 2024 Healthcare Conference on May 14, 2024, presenting comprehensive pain treatment solutions. A webcast of the event will be available on the company's website.
Nevro Corp. reported its first-quarter 2024 financial results along with additional restructuring steps to boost profitability. The company raised its adjusted EBITDA guidance, reaffirmed revenue guidance for 2024, and promoted Christofer Christoforou to COO. Revenue grew to $101.9 million, with a net loss from operations of $35.8 million and adjusted EBITDA loss of $9.6 million. The company's improved gross margin, operating expenses, and cash position were highlighted. Full-year revenue guidance stands at $435 million to $445 million, with adjusted EBITDA guidance revised to a range of negative $5 million to positive $2 million for 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.